GRS Home

The Growth Hormone Research Society


The 10th International Congress of the Growth Hormone Research Society
May10-11, 2024 - Stockholm, Sweden

Date and time
Friday 10 - Saturday 11 May 2024. This event will start at approximately 09:00 on Friday and will finish in time for delegates to attend the ECE 2024 Opening Ceremony.

ECE 2024 venues - Stockholmsmässan (, Room TBC

The meeting will provide an update on basic, translational and clinical research in the field of growth hormone related diseases. The format includes plenaries from leading experts in the field, and abstract based oral and poster sessions.
Follow this link for the program

Submission of Abstracts
Abstracts for this Congress must be submitted by email to the Growth Hormone Research Society (GRS): Guidelines for preparation and submission of abstracts can be found here. Abstract submission deadline for the GRS congress is Friday 1 March 2024. Notification to authors of abstract acceptance/rejection - Mid-March 2024.

GRS and ESE encourage that abstracts submitted to the GRS congress are also submitted to ECE 2024 and published in Endocrine Abstracts. Note that abstract submission deadline for ECE is Monday 22 January 2024. For more details about submission of abstracts to ECE 2024 please refer to

NB - You must be registered for the corresponding Congresses in order to present or be published at either meeting.

Delegate fee (GRS congress only)
In-person = 100 Euro
In-person (in-training, nurse, Early Career) = 50 Euro

NB - there is not an option to attend this congress online. The registration fees shown here do not include registration for ECE2024.

Travel grants
More than 50 travel grants are available from GRS for early career attendees who present an abstract.
Follow this link for details

Registration details
You must register for this event through your ECE 2024 registration (you do not have to attend ECE 2024, but your registration will only be valid for the Pre-Congress Course).
Follow this link to register

For further information, please contact the ECE 2024 Congress team on or send an email to GRS at

Human Growth Homone Indications

FDA approved uses of GH according to the DEA and updated in Aug 2009

In children hGH is approved for the treatment of poor growth due to Turner’s syndrome, Prader-Willi syndrome, and chronic renal insufficiency, hGH insufficiency/deficiency, for children born small for gestational age, and for idiopathic short stature. Accepted medical uses in adults include but are not limited to the treatment of the wasting syndrome of HIV/AIDS and hGH deficiency.

Updated Guidelines for GH Therapy 2003

In August 1996, the FDA approved GH for use in adult patients with GHD. The only approved indication was pituitary disease from known causes, including pituitary tumor, pituitary surgical damage, hypothalamic disease, irradiation, trauma, and reconfirmed childhood GHD. Most patients considered for GH therapy are in one of these categories. A few patients with definite GHD, however, have other kinds of pituitary-hypothalamic disease; these include patients with Sheehan’s syndrome, autoimmune hypophysitis, or hypophysitis associated with other inflammatory conditions, such as sarcoidosis..."

The US FDA has approved GH for use in the following pediatric conditions:
• Growth hormone deficiency
• Turner syndrome
• Chronic renal insufficiency
• Small for gestational age or intrauterine growth retardation
• Prader-Willi syndrome
• Continued height deficit at puberty."

New indications for GH 2005 has a table summarizing the use of growth hormone (GH) therapy in short stature both in the US and Europe:

Treatment recommended by NICE (National Institute for Clinical Excellence) guidelines 2002 in the UK
• GH deficiency, isolated or as part of multiple pituitary hormone deficiency
• Turner syndrome
• Prader Willi syndrome
• Short stature associated with chronic renal failure

Licensed indications in Europe
• GH deficiency, isolated or as part of multiple pituitary hormone deficiency
• Turner syndrome
• Prader Willi syndrome
• Short stature associated with chronic renal failure
• Short stature associated with low birth weight

Licensed in the USA, but not in Europe
• Idiopathic short stature
Short stature conditions where there have been trials of treatment with GH but outcome is not clear (not licensed indications)
• Noonan syndrome
• Skeletal dysplasia
• Rheumatoid arthritis
• Down syndrome
• Short stature associated with prolonged steroid use
• Aarskog’s syndrome





Consensus Statements


Honorary Members


hGH Indications



IGF Society